Post by Johan on Nov 2, 2024 18:55:43 GMT -4
Interleukin-4 (IL-4) is a critical factor in ovarian cancer's resistance to immunotherapy. Ovarian cancer cells produce IL-4 to create a protective tumor microenvironment that hinders immune cell infiltration, thereby reducing the effectiveness of immunotherapies. To counteract this mechanism, drugs that inhibit IL-4 signaling are being considered. One such drug is dupilumab, an IL-4 receptor antagonist currently approved for treating asthma and eczema. By blocking IL-4 activity, dupilumab can potentially disrupt the tumor's protective environment, thereby enhancing the efficacy of immunotherapies in ovarian cancer patients.
See the full article in NEWS-MEDICAL:
www.news-medical.net/news/20241101/New-therapeutic-target-overcomes-ovarian-cancer-immunotherapy-resistance.aspx
------------------------------
anticancersynergies.com/